Aignostics Introduces Advanced Application for Tumor Profiling
Atlas H&E-TME empowers researchers with fast analysis capabilities
In a significant development for cancer research, Aignostics has launched Atlas H&E-TME, an innovative application that streamlines the analysis of tumor microenvironments (TME) using hematoxylin and eosin (H&E) images. This application addresses a major challenge in cancer studies by allowing researchers to gain deep insights from standard H&E slides without the need for complex staining techniques. With this tool, researchers can analyze whole-slide images within hours, facilitating a quicker understanding of immune cell distributions, tissue structures, and spatial relationships across various cancer types.
Key Features of Atlas H&E-TME
Atlas H&E-TME is built on the cutting-edge Atlas foundation model, developed collaboratively by Aignostics, Mayo Clinic, and Charité Berlin. This application offers comprehensive analyses including quality control metrics, diverse tissue types, and multiple cell classes. It presents over 5,000 advanced quantitative metrics per image, ensuring detailed evaluations are available to users. This design also includes extensive validations carried out across different labs and scanner settings, ensuring its applicability in real-world scenarios.
Insights from Aignostics Leaders
The significance of this application has been echoed by Aignostics’ leaders. Frederick Klauschen, MD, a co-founder of the company and the Director at the Institute of Pathology at Ludwig-Maximilians-Universität München, highlighted the accuracy and reliability of the model across various cancer types. Viktor Matyas, Co-Founder and CEO, expressed the need for effective approaches in understanding TME to foster the development of potent cancer therapies. He emphasized that Atlas H&E-TME is a game-changer, delivering quality results with unprecedented accuracy and speed.
Diverse Research Applications
Atlas H&E-TME supports a variety of research scenarios. It can quickly identify and characterize tumors with immune infiltration and integrate H&E data with spatial transcriptomics for in-depth cell niche analyses. Initially, this application will be available to biopharma companies focusing on breast, bladder, colorectal, liver, and lung cancers. Future expansions will cater to academic researchers, broadening the scope of available cancer types and analysis methods.
About Aignostics
Aignostics, established in 2020, is at the forefront of artificial intelligence in pathology, transforming complex data into actionable insights for precision medicine. By combining unique access to a wealth of clinical data with advanced AI methodologies, Aignostics develops leading-edge products that span the entire drug development lifecycle, from initial research to clinical trials and diagnostic applications. Their latest offering, Atlas H&E-TME, stands out as a self-service solution for comprehensive tumor microenvironment analysis, providing researchers with remarkable precision and scalability.
Contact Information
For more information and inquiries, interested organizations can reach out through:
Lisa Zheng
[Email contact not provided]
With more than 120 talented employees and operations in Berlin and New York, Aignostics is backed by prominent investors and is actively engaged in pioneering advancements in cancer research.
Frequently Asked Questions
What is Atlas H&E-TME?
Atlas H&E-TME is an application developed by Aignostics for analyzing tumor microenvironments using H&E images, providing rapid and detailed insights.
How does Atlas H&E-TME improve cancer research?
This application allows for quick analyses of whole-slide images, helping researchers efficiently characterize tumors and their microenvironments.
Who can access Atlas H&E-TME?
Initially, access will be offered to biopharma partners, with academic access planned for future release to expand its usability in research.
What are the key benefits of using Atlas H&E-TME?
The application provides high accuracy, speed, and a comprehensive set of metrics, greatly enhancing the research capabilities within cancer studies.
How was Atlas H&E-TME developed?
Aignostics co-developed Atlas H&E-TME with leading institutions, ensuring robust validation and applicability across various research environments.
